Novo Nordisk A/S (NVO)vsShopify Inc (SHOP)
NVO
Novo Nordisk A/S
$36.33
-1.52%
HEALTHCARE · Cap: $165.02B
SHOP
Shopify Inc
$118.42
+1.95%
TECHNOLOGY · Cap: $151.59B
Smart Verdict
WallStSmart Research — data-driven comparison
Novo Nordisk A/S generates 2574% more annual revenue ($309.06B vs $11.56B). NVO leads profitability with a 33.1% profit margin vs 10.6%. NVO appears more attractively valued with a PEG of 4.88. NVO earns a higher WallStSmart Score of 55/100 (C).
NVO
Buy55
out of 100
Grade: C
SHOP
Hold48
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-59.4%
Fair Value
$24.21
Current Price
$36.33
$12.12 premium
Margin of Safety
-1729.9%
Fair Value
$6.39
Current Price
$118.42
$112.03 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Attractively priced relative to earnings
Every $100 of equity generates 61 in profit
Keeps 33 of every $100 in revenue as profit
Strong operational efficiency at 44.5%
Large-cap with strong market position
Revenue surging 30.6% year-over-year
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Large-cap with strong market position
Strong operational efficiency at 20.3%
Areas to Watch
Weak financial health signals
Expensive relative to growth rate
Revenue declined 7.6%
Earnings declined 4.7%
Trading at 11.5x book value
Weak financial health signals
Expensive relative to growth rate
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : NVO
The strongest argument for NVO centers on P/E Ratio, Return on Equity, Profit Margin. Profitability is solid with margins at 33.1% and operating margin at 44.5%.
Bull Case : SHOP
The strongest argument for SHOP centers on Revenue Growth, Debt/Equity, Altman Z-Score. Revenue growth of 30.6% demonstrates continued momentum.
Bear Case : NVO
The primary concerns for NVO are Piotroski F-Score, PEG Ratio, Revenue Growth.
Bear Case : SHOP
The primary concerns for SHOP are Price/Book, Piotroski F-Score, PEG Ratio. A P/E of 123.6x leaves little room for execution misses.
Key Dynamics to Monitor
NVO profiles as a declining stock while SHOP is a growth play — different risk/reward profiles.
SHOP carries more volatility with a beta of 2.90 — expect wider price swings.
SHOP is growing revenue faster at 30.6% — sustainability is the question.
SHOP generates stronger free cash flow (715M), providing more financial flexibility.
Bottom Line
NVO scores higher overall (55/100 vs 48/100), backed by strong 33.1% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novo Nordisk A/S
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novo Nordisk A / S, a healthcare company, is dedicated to the research, development, manufacture and marketing of pharmaceutical products globally. The company is headquartered in Bagsvaerd, Denmark.
Shopify Inc
TECHNOLOGY · SOFTWARE - APPLICATION · USA
Shopify Inc., a commerce company, offers a commerce and service platform in Canada, the United States, the United Kingdom, Australia, Latin America, and internationally. The company is headquartered in Ottawa, Canada.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?